Initial volume of a drug before it reaches the volume of distribution: Pharmacokinetics of F(ab′)2 antivenoms and other drugs

Toxicon

Volumn 50, Issue 5, 2007, Pages 653-665

  Sevcik, Carlos ^a   Salazar, Victor ^b   Díaz, Patricia ^a   D'Suze, Gina ^a  

^a IVIC CBB   (Venezuela)

^b INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Antivenom; Distribution volume; F(ab )2; Immunotherapy; Pharmacokinetics

Indexed keywords

CLEVIDIPINE; DIGITOXIN; DIGOXIN; LIDOCAINE; SCORPION VENOM; THIOPENTAL; VENOM ANTISERUM;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL WALL; CONNECTIVE TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FLUORESCENCE MICROSCOPE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIVENINS; ARTERIES; CAPILLARIES; ENDOTHELIUM, VASCULAR; HALF-LIFE; IMMUNOGLOBULIN FAB FRAGMENTS; INTESTINES; KIDNEY; LIVER; MALE; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; PORTAL SYSTEM; SCORPION VENOMS; SCORPIONS; SPLEEN; TIME FACTORS; TISSUE DISTRIBUTION;

SCORPIONES; TITYUS;

EID: 34548656546     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2007.05.011     Document Type: Article

References (32)

1. Anonymous, 2004. Collection of terms, symbols, equations, and explanations of common pharmacokinetic and pharmacodynamic parameters and some statistical functions. In: Pechstein, B., Cawello, W. (Eds.), Association for Applied Human Pharmacology (AGAH). AGAH Working Group on PK-PD modeling. 〈http://www.agah.info/uploads/media/PK-glossary_PKworking_group_2004_Ol.pdf〉.
2. Apostol T.M. Calculus vol. I (1961), Blaisdell Publishing Co., Waltham, MA pp. 34-37
3. Bhatti R.A., Yu S., Boulanger A., Fariss R.N., Guo Y., Bernstein S.L., Gentleman S., and Redmond T.M. Expression of 3-carotene 15,15-monooxygenase in retina and RPE-choroid. Invest. Ophthalmol. Vis. Sci. 44 (2003) 44-49
4. Brodie B.B., Bernstein E., and Mark L. The role of body fat in limiting the duration of action of thiopental. J. Pharmacol. Exp. Ther. 105 (1952) 421-426
5. Bucci M.R., Gratton J.-P., Rudic R.D., Acevedo L., Roviezzo F., Cirino G., and Sessa W.C. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6 (2000) 1362-1367
6. Chiou W.L. A simple equation to estimate the fraction of drug remaining in the body after an intravenous injection. J. Pharm. Pharmacol. 34 (1972) 342-343
7. Corada M., Mariotti M., Thurston G., Smith K., Kunkel R., Brockhaus M., Lampugnani M.G., Martin-Padura I., Stoppacciaro A., Ruco L., McDonald D.M., Ward P.A., and Dejana E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. USA 96 (1999) 9815-9820
8. Dahlquist D., and Björk A. Numerical Methods (1969), Prentice-Hall, Inc., Englewood Cliffs, NJ pp. 26-36
9. Danielson B.G. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am. Soc. Neprol. 15 (2004) S93-S98
10. Ericsson H., Bredberg U., Ericsson U., Jolin-Mellgard A., Nordlander M., and Regardt C.G. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology 92 (2000) 993-2001
11. Freitas Jr. R.A. Nanomedicine, vol. 1: Basic Capabilities (1999), Landes Biosciences, Georgetown, TX (Chapter 8, Section 8.2.1.2)
12. Geisser P., Baer M., and Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Aezheim. Forsch. 42 (1992) 1439-1452
13. Gibaldi M., and Perrier D. Pharmacokinetics. second ed (1982), Marcel Dekker Inc., New York, NY
14. Gobburu J.V.S., and Holford N.H.G. Vz, the terminal phase volume: time for its terminal phase. J. Biopharm. Stat. 11 (2001) 373-375
15. Green R., Charlton R.W., Seftel H., Bothwell T., Mayet F., Adams B., Finch C., and Layrisse M. Body iron excression in man. A collaborative study. Am. J. Med. 45 (1968) 336-353
16. Gutiérrez J.-M., Leon G., and Lomonte B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin. Pharmacokinet. 42 (2003) 721-741
17. 2 and F(ab) fractions of scorpion and snake antivenins: merits and potential for therapeutic use. Toxicon 36 (1998) 1523-1528
18. Kuipers J.A., Boer F., de Roode A., Olofsen E., Bovill J.G., and Burm A.G.L. Modelling population pharmacokinetics of lidocaine. Should cardiac output be included as a patient factor?. Anesthesiology 94 (2001) 566-573
19. Levy J.H., Huraux C., and Norlander M. Treatment of perioperative hypertension. In: Epstein M. (Ed). Calcium Antagonists in Clinical Medicine (1997), Hanley and Belfus, Philadelphia pp. 345-358
20. Niazi F. Volume of distribution as a function of time. J. Pharm. Sci. 65 (1976) 452-454
21. 2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administration. Pharmaceut. Res. 12 (1995) 1470-1473
22. 2-scorpion venom interactions. Toxicol. Appl. Pharmacol. 141 (1996) 272-277
23. Ochs H.R., Grube E., Greenblat D.J., Arendt R., and Bodem G. Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin. Klin. Wochenschr. 59 (1981) 889-897
24. Quesada L., Sevcik C., Lomonte B., Rojas E., and Gutierrez J.M. Pharmacokinetics of whole IgG equine antivenom: comparison between normal and envenomed rabbits. Toxicon 48 (2006) 255-263
25. Rivière G., Choumet V., Audebert V., Saboraud A., Debray M., Scherrmann J.-M., and Bon C. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. J. Pharmacol. Exp. Ther. 281 (1997) 1-8
26. Rowland M., and Tozer T.N. Clinical Pharmacokinetics. Concepts and Applications. third ed (1995), Lippincott, Williams & Wilkins, Philadelphia
27. Sevcik C. Letter to the editor. J. Biopharm. Stat. 16 (2006) 123-124
28. 2 extrusion mechanism from blood to tissues. Toxicon 44 (2004) 731-734
29. 2 scorpion antivenom in healthy human volunteers. Toxicon 46 (2005) 797-805
30. Wada R.D., Bjorkman S., Ebling W.F., William F., Harashima H., Harapat S.R., and Stanski D.R. Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology 87 (1997) 884-899
31. Yamamoto T., Tada T., Brodsky S.V., Tanaka H., Noiri E., Kajiya F., and Goligorsky M.S. Intravital videomicroscopy of peritubular capillaries in renal ischemia. Am. J. Physiol. Renal Physiol. 282 (2002) F1150-F1155
32. Zhu L.-J., Hardy M.P., Inigo I.V., Huhtaniemi I., Bardin C.W., and Moo-Young A.J. Effects of androgen on androgen receptor expression in rat testicular and epididymal cells: a quantitative immunohistochemical study. Biol. Reprod. 63 (2000) 368-376